Proactive Investors - Run By Investors For Investors

Cellmid managing director and CEO lifts holding in life sciences company with on-market purchase

The company told Proactive Investors in February that it remained on track for record revenues in financial year 2019, targeting profitability in financial year 2020.
Cellmid managing director and CEO lifts holding in life sciences company with on-market purchase
The company sells clinically validated anti-ageing products for hair, skin and body

Cellmid Limited (ASX:CDY) director Maria Halasz has demonstrated her confidence in the company with the purchase of 39,000 indirect shares at 21 cents a share in on-market trades.

The managing director and chief executive officer increased her holding to 1,585,938 fully paid ordinary shares.

READ: Cellmid’s évolis Professional product range to be sold in Europe

Last month the company registered its évolis Professional anti-ageing hair care products for sale in the European Union and the UK.

This represented the final step in a comprehensive regulatory compliance assessment of the products before they could be freely sold in Europe.

Cellmid also established a partnership with one of the largest cosmetics retailers in Europe and expects e-commerce sales on the partner’s platform will begin in the first half of the 2020 financial year.

READ: Cellmid alopecia patent granted in Europe for évolis hair therapy

The évolis Professional product range of all 11 SKUS will be sold in EU member states by Cellmid’s cosmetic retail partner.

Consistent with the company’s strategic plan released to the market at the end of February, the EU product registration represents yet another important milestone in the company’s plans for the global expansion of the évolis brand.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use